Results 41 to 50 of about 12,993 (261)

Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma

JGH Open, 2022
Background and Aim The risk of hepatocellular carcinoma (HCC) persists in a condition of sustained virologic response (SVR) after hepatitis C virus (HCV) eradication.
Keishi Sugimachi, Hiromitsu Araki, Hideyuki Saito, Takaaki Masuda, Fumihito Miura, Kentaro Inoue, Tomonari Shimagaki, Yohei Mano, Tomohiro Iguchi, Masaru Morita, Yasushi Toh, Tomoharu Yoshizumi, Takashi Ito, Koshi Mimori   +13 more
doaj   +1 more source

Platelet count and sustained virological response in hepatitis C treatment

World Journal of Hepatology, 2013
To examine the epidemiological data, hematological safety and treatment responses of peginterferon-alpha 2a plus ribavirin therapy for hepatitis C.Between March 2008 and February 2011, 196 hepatitis C virus (HCV) genotype 1 infected Japanese (127 treatment-naive and 69 treatment-experienced patients) patients treated with peginterferon-alpha 2a plus ...
Tatsuo, Kanda, Keizo, Kato, Akihito, Tsubota, Nobuo, Takada, Takayoshi, Nishino, Shigeru, Mikami, Tatsuo, Miyamura, Daisuke, Maruoka, Shuang, Wu, Shingo, Nakamoto, Makoto, Arai, Keiichi, Fujiwara, Fumio, Imazeki, Osamu, Yokosuka   +13 more
openaire   +2 more sources

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis

Viruses, 2023
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, while
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel   +14 more
doaj   +1 more source

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

Advanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li, Yunjie Lu, Ziyan Huang, Jianjiang Chen, Yanbin Liu, Lei Qin, Chao Wang, Yumin Wu   +7 more
wiley   +1 more source

The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study

The Korean Journal of Gastroenterology, 2018
Background /Aims: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients.
Seong Jun Park, Ah Ran Kim, Won Hyeok Choe, Jeong Han Kim, Byung Chul Yoo, So Young Kwon   +5 more
doaj   +1 more source

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era

Gut and Liver, 2017
Background/AimsTo evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection.
Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong   +7 more
doaj   +1 more source

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2019
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks
Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang   +11 more
doaj   +1 more source

Modern pharmacotherapy of chronic hepatitis C in patients who failed to achieve sustained virologic response [PDF]

Annals of Mechnikov's Institute, 2020
Introduction. According to WHO experts, about 150 million people suffer from chronic viral hepatitis C (CHC), and 350,000 die annually as a result of liver damage by the hepatitis C virus (HCV).
Kireyev, I.V., Zhabotynska, N.V.
doaj   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

Animal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam, Aashika Raagavi Jeanpierre, Salma Mohammed, Rajesh Srinivasan, Aman Kumar Mohanty   +4 more
wiley   +1 more source